USPTO Patent Applications - Biotech (C12N)

CRISPR-Cas Type I-F3 Transposon Systems for DNA Integration Patent Application

USPTO published patent application US20260110001A1 disclosing recombinant Type I-F3 transposon-associated CRISPR-Cas systems and methods for DNA integration. The application, filed June 7, 2023 by inventors Rodolphe Barrangou and Avery Roberts under application number 18872321, covers CRISPR-Cas nucleic acid constructs combined with Tn7-like transposon systems. This publication makes the invention publicly available for examination and potential licensing or competing development.

TNAP Marker Isolates Adult Multipotential Cells, Mesoblast

Mesoblast, Inc. has filed USPTO patent application US20260109783A1 (Application No. 19080304), published April 23, 2026, covering the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and isolating adult multipotential cells. The application names Stan Gronthos, Andrew Christopher William Zannettino, and Paul John Simmons as inventors and discloses cell populations enriched by the disclosed methods along with therapeutic uses of these cells. The filing date was March 14, 2025.

Phage-Derived Particles Deliver DNA Into C. Acnes, Eligo Bioscience

USPTO published patent application US20260109991A1 by Eligo Bioscience on April 23, 2026, covering phage-derived particles for delivering DNA payloads into Cutibacterium acnes bacteria. The application, filed October 24, 2025, discloses engineered vectors with C. acnes phage packaging signals and genes of interest, along with producer cells, phage-derived particles, and methods for transducing C. acnes with transgenes. Inventors include Aymeric LEVEAU, Ines CANADAS BLASCO, Aurelie MATHIEU, and Antoine DECRULLE.

Juno Therapeutics Patents BCMA-Specific CARs for Immunotherapy

Juno Therapeutics, Inc. has published a patent application (US20260109774A1) for chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA) and encoding polynucleotides, published April 23, 2026. The application covers anti-BCMA antibodies, antigen-binding fragments, and genetically engineered cells expressing the CARs for use in adoptive cell therapy. The invention includes human antibodies that compete for BCMA binding with reference antibodies and is directed toward immunotherapy applications including potential cancer treatments.

BDNF Gene Therapy Targets Obesity, Metabolic Disorders

The USPTO has published patent application US20260109997A1 for BDNF expression constructs and vectors intended to treat metabolic disorders including obesity. The application, filed on October 11, 2023 by five named inventors including Alexandria Forbes and Matthew During, claims the disclosed gene therapy is more effective than existing BDNF-based gene therapy constructs for metabolic indications.

Duchenne Muscular Dystrophy Treatment, University of Pennsylvania

The USPTO published patent application US20260109998A1 by The Trustees of the University of Pennsylvania, covering triple-splice mutants of dystrophin or utrophin, viral vectors encoding them, and compositions for treating Duchenne Muscular Dystrophy in human patients. Inventor Hansell Stedman filed the application on September 15, 2025, with CPC classifications C12N 15/86 and C07K 14/4708 indicating biotech/pharmaceutical subject matter. The application is published under Application No. 19328483.

Nucleic Acid Complexes with Cationic/Anionic Polymers and RNA Molecules

The USPTO published patent application US20260096998A1 for nucleic acid complexes comprising cationic polymers, anionic polymers, and monomeric RNA molecules. The disclosed complexes feature a core structure where the cationic polymer and RNA molecule are encapsulated by the anionic polymer. The application covers linear and non-linear configurations of these complexes for therapeutic uses.

Thraustochytrids, Fatty Acid Compositions, and Methods - DSM Assets

USPTO published patent application US20260096578A1 by DSM IP Assets B.V. covering isolated thraustochytrid microorganisms, microbial oils, biomasses, compositions, and associated production and use methods. The application, filed August 13, 2025, lists six inventors and covers CPC classifications spanning food, cosmetic, and pharmaceutical applications.

Microbial Compositions and Methods for Fermented Foods

USPTO published patent application US20260096563A1 for microbial compositions comprising purified populations of microorganisms used in producing dough or baked food products. The compositions are designed to enhance fermentation by improving rheological properties, nutritional quality, and shelf-life of dough and baked food products. The application was filed on December 9, 2025, with inventors Cameron Martino and James Gaffney.

Patent for RSV vaccine using F protein trimer prefusion conformation

Patent for RSV vaccine using F protein trimer prefusion conformation

Phio Pharmaceuticals T Cell Induction Method for Cancer Treatment

USPTO published patent application US20260097120A1 assigned to Phio Pharmaceuticals Corp. The application covers methods for producing immunogenic compositions using ex vivo T cell treatment with oligonucleotide agents capable of controlling T cell differentiation through PD-1 silencing via chemically modified double-stranded nucleic acid molecules. The disclosed compositions and methods target cancer treatment, including melanoma.

Biallelic Knockout CISH Gene, RNA Compositions

USPTO published patent application US20260097121A1 by inventor Rafi Emmanuel covering RNA compositions with guide sequences targeting the CISH gene for biallelic knockout. The application includes sequences defined by SEQ ID NOs 1-6838 and methods for their use. Filing date was September 18, 2023, under application number 19113098.

Biallelic CIITA Knockout Patent, 34199 RNA Sequences

USPTO published patent application US20260097123A1 for compositions and methods for biallelic CIITA knockout using RNA molecules comprising guide sequences of 17-50 nucleotides. The application covers 34,199 sequences (SEQ ID NOs 1-34199). Inventor: Rafi Emmanuel. Filing date: September 19, 2023.

G47ΔhIL12A Oncolytic HSV for Glioblastoma and Triple-Negative Breast Cancer Treatment

USPTO published patent application US20260097135A1 for G47ΔhIL12A, an oncolytic herpes simplex virus (oHSV) engineered with human IL-12 transgene driven by HCMV IE enhancer/promoter. The invention addresses augmented transgene production and increased virus replication while maintaining safety profiles. Applications include treatment of glioblastoma (GBM) and triple-negative breast cancer (TNBC). Filing date: September 26, 2023; Application No. 19114912.

Controlled Movement Method for Gametes, Zygotes, Embryos

USPTO published patent application US20260098250A1 assigned to CIC nanoGUNE, filed September 6, 2023, covering a method and device for controlled movement of gametes, zygotes, and embryos using micro-scale carriers. The device comprises biocompatible carriers with maximum 500 μm dimensions that can releasably connect to biological cells and move autonomously or via external influences. The technology aims to enable less invasive procedures and higher implantation rates in reproductive medicine and healthcare applications.

Novozymes A/S Patent for Enzymatic Plant Protein Extract Method

USPTO published patent application US20260096575A1 assigned to Novozymes A/S for an enzymatic method of producing plant protein extract. The method involves treating plant protein raw materials under alkaline conditions with protein deamidase added before, during, or after treatment, followed by protein recovery and spray drying. The resulting plant protein extract has improved solubility suitable for food or beverage applications. The application was filed on September 28, 2023.

Ultra-High Molecular Weight Xanthan Gum Engineered Strain and Detection Marker

The USPTO published patent application US20260098104A1 for an engineered bacterial strain that produces ultra-high molecular weight xanthan gum with molecular weight exceeding 2.0×10^7 Da, significantly above the ordinary range of 0.2×10^7-2.0×10^7 Da. The application also discloses a molecular marker for detecting the engineered strain and its processed products, enabling rapid identification in production and quality control contexts.

Dura Mater-Derived Stem Cells and Method for Producing the Same

USPTO published patent application US20260098243A1 for dura mater-derived stem cells and production methods. Inventors: Sun Hwa PARK, Sung Won KIM, Seung Ho YANG, Jung Eun LEE, Hyun Ji LEE. The application, filed 2025-10-06 under Application No. 19350367, covers methods of isolating stem cells from dura mater with serum supplements and their use in cell therapeutic agents.

Harvard Patent - Automated Parallel Chromatography for Extracellular Vesicle Purification

USPTO published patent application US20260098244A1 from President and Fellows of Harvard College disclosing devices and methods for automated parallel chromatography for purification of extracellular vesicles from biological samples. The invention includes a pump, computing device, and a stand with columns containing resin and bottom wells or tubes. CPC classifications indicate applications in cell/vesicle technology and chromatography methods.

Stem Cell Differentiation Method for Progenitor Cells and Organoids

The USPTO published patent application US20260098245A1 assigned to Koninklijke Nederlandse Akademie Van Wetenschappen (Royal Netherlands Academy of Arts and Sciences). The application, filed December 10, 2025, covers differentiation methods for progenitor cells including mammalian epithelial stem cells, differentiation media compositions for use in said methods, organoids and cells obtainable by said methods, and therapeutic uses thereof. Inventors are Johannes Carolus Clevers and Helmuth Gehart.

Ureteric Bud Kidney Tissue Engineering Compositions and Methods

The USPTO published patent application US20260098246A1 disclosing engineered ureteric bud kidney tissues and methods for making lumenized kidney tissues with spatially-controlled 3D tubular architecture. The application includes in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Inventors: Benjamin Shepherd, Alice Chen, J. William Higgins, III. Filed July 30, 2025.

Solid-State Storage of Biochemical Systems Patent Application

USPTO published patent application US20260098247A1 by inventor Javin Oza disclosing compositions and methods for solid-state storage of biological systems using polymeric cryoprotectants, saccharide cryoprotectants, emulsifiers, and lubricating flow agents, enabling cold chain-free, point-of-care platforms for diagnostics, research, biomanufacturing, and testing.

Lipid-Encapsulated Dual-Cleaving Endonuclease for DNA and Gene Editing

USPTO published patent application US20260098248A1 for a lipid-encapsulated dual-cleaving endonuclease enabling non-viral gene editing methods, filed October 10, 2025 under application number 19355897. Inventors include David R. Edgell, Thomas A. McMurrough, Brent E. Stead, and Odisho K. Israel. The invention covers methods of administering a chimeric nuclease to cells or organisms without viral vectors.

Methods for Producing Highly Purified (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate for Enhancing Bodily Function and Treating Disease States

USPTO published patent application US20260098281A1 by Romeo Tango, LLC for methods of producing highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. The application covers therapeutic applications including inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additional applications include improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection.

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

Circular DNA Purification Using Nanoclays

USPTO published patent application US20260098252A1 by Texas State University (filed October 3, 2025) disclosing a method of purifying circular DNA from samples using nanoclays that preferentially adsorb contaminants including non-circular DNA, RNA, proteins, and endotoxins while leaving circular DNA unbound. The elution-free method separates nanoclay-contaminant complexes from the enriched circular DNA fraction. The invention also covers compositions and systems for such purification and methods of refining nanoclays for the purification process.

Lysis Vessel with Dual Membranes and Non-Magnetic Beads for On-Board Cell Lysis

USPTO published patent application US20260098253A1 assigned to Gen-Probe Incorporated. The application covers a lysis vessel for performing cell lysis that includes a laterally extending member and sleeve with dual porous membranes, non-magnetic beads, and at least one magnetic element contained within a lysis chamber. Filing date was December 11, 2025, under application number 19416385.

Methods of Improving Unique Molecular Index Ligation Efficiency

Illumina, Inc. has filed a patent application (US20260098256A1) for methods and adapter pools that improve unique molecular index (UMI) ligation efficiency in nucleic acid sequencing applications. The invention enables more accurate quantification of polynucleotide fragments by providing UMIs that are uniquely associable with individual fragments. The application was published April 9, 2026, with a filing date of December 12, 2025. Biotechnology companies developing next-generation sequencing technologies may need to review this application to assess potential impacts on their IP strategies or freedom-to-operate analysis. Researchers and diagnostic developers using UMI-based sequencing methods should monitor this and related patent activity for potential licensing implications.

BEST1 Vectors for Retinal Dystrophy Treatment

The USPTO published patent application US20260098277A1 covering BEST1-targeted expression constructs, nucleic acid vectors, and pharmaceutical compositions for treating BEST1-associated retinal dystrophies including autosomal dominant bestrophinopathies. The application includes BEST1-targeted shRNAs, BEST1 coding sequences, promoters, and regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations. This published application represents an early-stage intellectual property filing with no granted rights or compliance obligations established.

CO2 Conversion to C2+ Chemicals via Electrochemical and Microbial Process

USPTO published patent application US20260098282A1 disclosing a method for converting carbon dioxide to higher value C2+ chemicals using an electrochemical cell with a carbon dioxide reducing catalyst combined with microbial conversion. The application was filed on September 23, 2023, by inventors Peng Zhang, Kainan Chen, Joshua Shuhua Yuan, and Susie Y. Dai. The publication makes the application publicly available but does not constitute a granted patent.

In Vitro Bioproduction of Polyhydroxyalkanoate Monomers

USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.

Cell-Free PPi-Driven ATP Regeneration Platform Patent

Cell-Free PPi-Driven ATP Regeneration Platform Patent

Methods for Assaying Enriched Nucleic Acids Using Complementary Probes

The USPTO published patent application US20260098304A1 covering methods for assaying enriched nucleic acids using probes with sequences complementary to RNA expression products to determine expression levels of multiple genes. The application was filed on October 3, 2024 by inventors including Charles M. Perou, Joel S. Parker, and others. The claimed methods enable enrichment of nucleic acid molecules for gene expression analysis in biological samples.

Protein Evolution System With DNA Synthesis, Microfluidics

The USPTO published patent application US20260098257A1 covering systems, methods, and kits for rapid protein evolution. The application (No. 19271120, filed July 16, 2025) names five inventors and describes a system combining DNA synthesis, microfluidic devices with sequestration pens, and a computing component for iterative protein optimization. The technology enables cell-free protein expression and assay-based evaluation of protein variants.

DNA Origami Nanostructures for Molecular Data Storage Patent Application

USPTO published patent application US20260098258A1 on April 9, 2026, disclosing compositions and methods using DNA origami principles to package and archive data stored in multiple indexed DNA oligonucleotides. The application (No. 19319178, filed September 4, 2025) covers DNA origami (DNAO) nanostructures enabling selective physical data access and retrieval from a molecular pool.

KWS SAAT Immature Inflorescence Meristem Gene Editing

KWS SAAT SE & Co. KGaA has published a patent application (US20260098273A1) for a method of plant genome modification targeting immature inflorescence meristem (IIM) cells. The method uses genome editing systems with optional regeneration boosters, delivered via particle bombardment, to modify genomic target sites in plant cells and regenerate modified plant tissues, organs, or seeds.

Root-Mediated Uptake of Guide RNA for Genomic Editing of a Plant

USPTO published patent application US20260098274A1 by Inari Agriculture Technology disclosing methods for editing plant genomes by delivering guide RNA to plant roots for CRISPR-Cas editing in meristems. Inventors include Aran McCay, Michael Lee Nuccio, and Palak Kathiria. The filing date was March 7, 2024.

UORF Editing to Improve Crop Plant Agronomic Traits

USPTO published patent application US20260098275A1 assigned to Inari Agriculture Technology, Inc., disclosing methods of improving agronomic traits in crop plants through editing sequences within the 5' untranslated region (5' UTR) of plant genomes. The application names Ross Everett Altman, Malachy T. Campbell, Karl Anton Grothe Kremling, and Ruijuan Li as inventors. Filing date was April 10, 2024.

Self-Circularized RNA Preparation Method, Apr 09

Self-Circularized RNA Preparation Method, Apr 09

Exon 44 Duchenne Muscular Dystrophy Cyclic Peptide Antisense

The USPTO published patent application US20260098262A9 covering compositions comprising a cyclic peptide and an antisense compound targeting exon 44 of the DMD gene for Duchenne Muscular Dystrophy treatment. The application was filed on August 30, 2022, under application number 18688083, listing nine inventors including Xiang Li, Ziqing Qian, and others. No compliance obligations or deadlines are associated with this publication. This patent application publication represents a formal administrative record from the USPTO but does not create any regulatory obligations or deadlines for affected parties. Pharmaceutical and biotechnology companies developing exon-skipping therapies for DMD may wish to review the claims for potential freedom-to-operate implications.

Modified Double-Stranded RNA Agents Inhibit Gene Expression

USPTO published patent application US20260098263A1 for modified double-stranded RNA (dsRNA) agents capable of inhibiting gene expression. The application was published April 9, 2026, with inventors Martin MAIER, Don FOSTER, Stuart MILSTEIN, Satya KUCHIMANCHI, Vasant JADHAV, Kallanthottathil RAJEEV, Muthiah MANOHARAN, and Rubina PARMAR. The dsRNA agents contain thermally destabilizing nucleotides positioned opposite the seed region of the antisense strand and modified nucleotides with reduced steric bulk, with pharmaceutical compositions and therapeutic methods for treating disease conditions also disclosed.

Methods and Compositions for Designing and Selecting TinyRNAs to Maximize Target Cleavage

USPTO published patent application US20260098266A1 by Kotaro NAKANISHI disclosing methods for designing and selecting tinyRNAs with guide RNA and Argonaute molecules for gene expression regulation in biotherapeutic and diagnostic applications. The application was filed April 1, 2024, and published April 9, 2026.

Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment

USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.

Genentech Modified CHO Cells for Therapeutic Protein Production

USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation

USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs. The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.

CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA

The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.

Cells, Organs with Modified Genes for Xenograft Tolerance

Cells, Organs with Modified Genes for Xenograft Tolerance

Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery

The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.

Low Dose Psilocybin in Foodstuff and Microbes for Same

USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.